Skip to content

The efficacy and safety evaluation of Medical Glue Embolization treatment in high-risk patients with acute peptic ulcer bleeding-- A prospective multicenter randomized controlled trail

The efficacy and safety evaluation of Medical Glue Embolization treatment in high-risk patients with acute peptic ulcer bleeding-- A prospective multicenter randomized controlled trail

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300071278
Enrollment
Unknown
Registered
2023-05-10
Start date
2023-05-15
Completion date
Unknown
Last updated
2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

peptic ulcer bleeding

Interventions

Experimental group:Medical Glue Embolization treatment
Control group:Treatment of peptic ulcer bleeding with one or two or more standard combination regiments includes: 1. Endoscopic drug injection treatment 2. Endoscopic digestive endoscopic hemostatic c

Sponsors

Affiliated Hospital of Zunyi Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-75 years, no gender limit; Hematemesis and/or black stool, blood loss such as dizziness, sweating, palpitation, shock, etc.; 2. Peptic ulcer with acute bleeding caused by various causes can be characterized by jet bleeding (Forrest Ia), active bleeding (Forrest Ib), and naked blood vessel diameter >=2mm (Forrest IIa grade) under endoscopy, as long as one of them is satisfied; 3. High risk of rebleeding (defined as Blatchford score >=6); 4. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients with high suspicion of malignant ulcer transformation; 2. Patients with other tumors; 3. Patients with varicose bleeding from portal hypertension; 4. Severe cardiopulmonary and cerebrovascular diseases, including acute myocardial infarction, severe conduction block and heart failure; Including severe lung infection, severe emphysema, pulmonary heart disease and respiratory failure; Including severe cerebral ischemia, severe cerebral infarction, etc. Suffering from other end-stage diseases; Patients who cannot accept or cooperate with endoscopic therapy; 5. Patients with peptic ulcer perforation requiring surgery; 6. Severe liver and kidney insufficiency; 7. The researcher considers that the candidate is not suitable; 8. Pregnant or lactating patients.

Design outcomes

Primary

MeasureTime frame
Success rate of hemostasis;

Secondary

MeasureTime frame
Retreatment intervention;

Countries

China

Contacts

Public ContactTuo Biguang

Affiliated Hospital of Zunyi Medical University

tuobiguang@aliyun.com+86 130 9679 0598

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026